Luc Deliens

Luc Deliens

Auto-generated profile, based on publicly available information

Luc Deliens

End-of-Life Care Research Group, Vrije Universiteit Brussel (VUB) & Ghent University, Ghent, Belgium

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2003 in The Lancet
Verified
Journal Article
Closed access
AHAgnes van der Heide
Agnes van der Heide
LDLuc Deliens
Luc Deliens
KFKarin Faisst
Karin Faisst
TNTore Nilstun
Tore Nilstun
MNMichael Norup
Michael Norup
PMPaul J van der Maas
Paul J van der Maas

16 February 2012 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
BGB. Gomes
B. Gomes
IHI. J. Higginson
I. J. Higginson
NCN. Calanzani
N. Calanzani
JCJ. Cohen
J. Cohen
LDL. Deliens
L. Deliens
RHRichard Harding
Richard Harding
Cancer end-of-life care (EoLC) policies assume people want to die at home. We aimed to examine variations in preferences for place of death cross-nationally. A telephone survey of a random sample of individuals aged ≥16 in England, Flanders, Germany, Italy, the Netherlands, Portugal and Spain. We determined where people would prefer to die if they had a serious illness such as advanced cancer, facilitating circumstances, personal values and experiences of illness, death and dying. Of 9344 participants, between 51% (95% CI: 48% to 54%) in Portugal and 84% (95% CI: 82% to 86%) in the Netherlands would prefer to die at home. Cross-national analysis found there to be an influence of circumstances and values but not of experiences of illness, death and dying. Four factors were associated with a preference for home death in more than one country: younger age up to 70+ (Germany, the Netherlands, Portugal, Spain), increased importance of dying in the preferred place (England, Germany, Portugal, Spain), prioritizing keeping a positive attitude (Germany, Spain) and wanting to involve family in decisions if incapable (Flanders, Portugal). At least two-thirds of people prefer a home death in all but one country studied. The strong association with personal values suggests keeping home care at the heart of cancer EoLC.

1 October 2014 in Journal of Pain and Symptom Management
Verified
Journal Article
Open access
KMKatrien Moens
Katrien Moens
IHIrene J. Higginson
Irene J. Higginson
RHRichard Harding
Richard Harding
SBSarah Brearley
Sarah Brearley
ACAugusto Caraceni
Augusto Caraceni
LBLieve Van Den Block
Lieve Van Den Block
If access to effective palliative care is to extend beyond cancer patients, an understanding of the comparative prevalence of palliative care problems among cancer and non-cancer patients is necessary. This systematic review aimed to describe and compare the prevalence of seventeen palliative care-related problems across the four palliative care domains among adults with advanced cancer, acquired immune deficiency syndrome, chronic heart failure, end-stage renal disease (ESRD), chronic obstructive pulmonary disease, multiple sclerosis, motor neuron disease, Parkinson's disease, and dementia. Three databases were searched using three groups of keywords. The results of the extraction of the prevalence figures were summarized. The electronic searches yielded 4697 hits after the removal of 1784 duplicates. Of these hits, 143 met the review criteria. The greatest number of studies were found for advanced cancer (n=57) and ESRD patients (n=47), and 75 of the 143 studies used validated scales. Few data were available for people living with multiple sclerosis (n=2) and motor neuron disease (n=3). The problems with a prevalence of 50% or more found across most of the nine studied diagnostic groups were: pain, fatigue, anorexia, dyspnea, and worry. There are commonalities in the prevalence of problems across cancer and non-cancer patients, highlighting the need for palliative care to be provided irrespective of diagnosis. The methodological heterogeneity across the studies and the lack of non-cancer studies need to be addressed in future research.

20 February 2014 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
DBDavid Blum
David Blum
GSG. B. Stene
G. B. Stene
TSTora Skeidsvoll Solheim
Tora Skeidsvoll Solheim
PFP. Fayers
P. Fayers
MHM. J. Hjermstad
M. J. Hjermstad
DLDeliens Luc
Deliens Luc
Weight loss limits cancer therapy, quality of life and survival. Common diagnostic criteria and a framework for a classification system for cancer cachexia were recently agreed upon by international consensus. Specific assessment domains (stores, intake, catabolism and function) were proposed. The aim of this study is to validate this diagnostic criteria (two groups: model 1) and examine a four-group (model 2) classification system regarding these domains as well as survival. Data from an international patient sample with advanced cancer (N = 1070) were analysed. In model 1, the diagnostic criteria for cancer cachexia [weight loss/body mass index (BMI)] were used. Model 2 classified patients into four groups 0-III, according to weight loss/BMI as a framework for cachexia stages. The cachexia domains, survival and sociodemographic/medical variables were compared across models. Eight hundred and sixty-one patients were included. Model 1 consisted of 399 cachectic and 462 non-cachectic patients. Cachectic patients had significantly higher levels of inflammation, lower nutritional intake and performance status and shorter survival. In model 2, differences were not consistent; appetite loss did not differ between group III and IV, and performance status not between group 0 and I. Survival was shorter in group II and III compared with other groups. By adding other cachexia domains to the model, survival differences were demonstrated. The diagnostic criteria based on weight loss and BMI distinguish between cachectic and non-cachectic patients concerning all domains (intake, catabolism and function) and is associated with survival. In order to guide cachexia treatment a four-group classification model needs additional domains to discriminate between cachexia stages.

1 September 2015 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
JCJ Cohen
J Cohen
LPL Pivodic
L Pivodic
GMG Miccinesi
G Miccinesi
BOB D Onwuteaka-Philipsen
B D Onwuteaka-Philipsen
WNW A Naylor
W A Naylor
LDL Deliens
L Deliens
Where people die can influence a number of indicators of the quality of dying. We aimed to describe the place of death of people with cancer and its associations with clinical, socio-demographic and healthcare supply characteristics in 14 countries. Cross-sectional study using death certificate data for all deaths from cancer (ICD-10 codes C00-C97) in 2008 in Belgium, Canada, Czech Republic, England, France, Hungary, Italy, Mexico, the Netherlands, New Zealand, South Korea, Spain (2010), USA (2007) and Wales (N=1 355 910). Multivariable logistic regression analyses evaluated factors associated with home death within countries and differences across countries. Between 12% (South Korea) and 57% (Mexico) of cancer deaths occurred at home; between 26% (Netherlands, New Zealand) and 87% (South Korea) occurred in hospital. The large between-country differences in home or hospital deaths were partly explained by differences in availability of hospital- and long-term care beds and general practitioners. Haematologic rather than solid cancer (odds ratios (ORs) 1.29–3.17) and being married rather than divorced (ORs 1.17–2.54) were most consistently associated with home death across countries. A large country variation in the place of death can partly be explained by countries’ healthcare resources. Country-specific choices regarding the organisation of end-of-life cancer care likely explain an additional part. These findings indicate the further challenge to evaluate how different specific policies can influence place of death patterns.

1 April 2010 in Journal of the American Geriatrics Society
Verified
Journal Article
Closed access
PDF file
DHDirk Houttekier
Dirk Houttekier
JCJoachim Cohen
Joachim Cohen
JBJohan Bilsen
Johan Bilsen
JAJulia Addington‐Hall
Julia Addington‐Hall
BOBregje D. Onwuteaka‐Philipsen
Bregje D. Onwuteaka‐Philipsen
LDLuc Deliens
Luc Deliens